Mr. Albert Beraldo reports

MEDICENNA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS

Medicenna Therapeutics Corp. has released the voting results from the company's annual meeting of shareholders, held today, Sept. 25, 2025.

All nominees listed in the management information circular dated Aug. 13, 2025, were elected as directors. The results of the vote are detailed in the attached table.

A total of 55.75 per cent of the issued and outstanding common shares of the company were represented in person and by proxy at the meeting. Dr. John H. Sampson did not stand for re-election at the meeting but will continue to support the company in a consulting capacity as a clinical adviser. Albert Beraldo, lead independent director, commented, "On behalf of my fellow board members and the Medicenna management team, I would like to thank Dr. Sampson for his dedicated service to the company over the years, as well as for his continued expertise and support."

Please refer to the circular available on SEDAR+ for more information on the business transacted at the meeting. A report on voting results will also be filed on SEDAR+.

About Medicenna Therapeutics Corp.

Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 superkines and first-in-class empowered superkines. Medicenna's long-acting IL-2 superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T-cells and NK-cells. Medicenna's IL-4 empowered superkine, bizaxofusp (formerly MDNA55), has been studied in five clinical trials enrolling over 130 patients, including a phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained fast-track and orphan drug status from the Food and Drug Administration and FDA/European Medicines Agency, respectively. Medicenna's early-stage high-affinity IL-2 beta-biased IL-2/IL-15 superantagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft versus host diseases. Medicenna's early-stage BiSKITs (bifunctional superkine immunotherapies) and the T-Mask (targeted metalloprotease activated superkine) programs are designed to enhance the ability of superkines to treat immunologically cold tumours.

We seek Safe Harbor.